serena williams ro glp 1 Weight Loss With - a GLP-1 Partnership Serena Williams has partnered with
Description
Contraindications : See shared GLP-1 CI/precautions above
doi:10.3389/fendo.2020.00478 157
Larger randomized placebo-controlled trials including a variety of patient populations (ie, those with metabolic syndrome versus those without) are needed to confirm efficacy of GLP-1RAs according to patient type
Incorrect dosing carries significant risks, including serious gastrointestinal complications and other adverse events
A July 2024 study found that people who were taking semaglutide were about 4 times more likely to develop NAION compared to the control group
Furthermore, theres a risk of depression and suicidal thoughts
